Ophthalmic Anti-Inflammatories
Therapeutic Class Review (TCR)

July 18, 2019

No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording, digital scanning, or via any information storage or retrieval system without the express written consent of Magellan Rx Management.

All requests for permission should be mailed to:

Magellan Rx Management
Attention: Legal Department
6950 Columbia Gateway Drive
Columbia, Maryland 21046

The materials contained herein represent the opinions of the collective authors and editors and should not be construed to be the official representation of any professional organization or group, any state Pharmacy and Therapeutics committee, any state Medicaid Agency, or any other clinical committee. This material is not intended to be relied upon as medical advice for specific medical cases and nothing contained herein should be relied upon by any patient, medical professional or layperson seeking information about a specific course of treatment for a specific medical condition. All readers of this material are responsible for independently obtaining medical advice and guidance from their own physician and/or other medical professional in regard to the best course of treatment for their specific medical condition. This publication, inclusive of all forms contained herein, is intended to be educational in nature and is intended to be used for informational purposes only. Send comments and suggestions to PSTCREditor@magellanhealth.com.
## FDA-APPROVED INDICATIONS

<table>
<thead>
<tr>
<th>Drug</th>
<th>Manufacturer</th>
<th>Indication(s)</th>
</tr>
</thead>
</table>
| dexamethasone (Maxidex®)                  | Alcon/Novartis                | ▪ Treatment of corticosteroid-responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe  
▪ Corneal injury                           |
| dexamethasone sodium phosphate            | generic                       | ▪ Treatment of corticosteroid-responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe  
▪ Corneal injury                           |
| difluprednate (Durezol®)                  | Alcon/Novartis                | ▪ Treatment of inflammation and pain associated with ocular surgery  
▪ Treatment of endogenous anterior uveitis |
| fluorometholone (FML®)                    | Allergan, Pacific/Greenstone  | ▪ Treatment of corticosteroid-responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe |
| fluorometholone (FML Forte®)              | Allergan                      | ▪ Treatment of corticosteroid-responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe |
| fluorometholone (FML S.O.P. *)            | Allergan                      | ▪ Treatment of corticosteroid-responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe |
| fluorometholone acetate (Flarex®)         | Alcon/Novartis                | ▪ Treatment of corticosteroid-responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe |
| loteprednol 1% suspension (Inveltys™)*     | Kala                          | ▪ Treatment of post-operative inflammation and pain following ocular surgery |
| loteprednol 0.5% gel, ointment (Lotemax®)* | Valeant/Bausch               | ▪ Treatment of post-operative inflammation and pain following ocular surgery |
| loteprednol 0.5% suspension (Lotemax®)     | generic, Valeant/Bausch       | ▪ Treatment of corticosteroid-responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe  
▪ Treatment of post-operative inflammation following ocular surgery |
| loteprednol 0.38% gel (Lotemax® SM)*       | Valeant/Bausch               | ▪ Treatment of post-operative inflammation and pain following ocular surgery |
| prednisolone acetate 1% (Omnipred®, Pred Forte®) | Alcon/Novartis, Allergan, Pacific/Greenstone*, Sandoz* | ▪ Treatment of corticosteroid-responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe  
▪ Treatment of corneal injury (Omnipred) |
| prednisolone acetate 0.12% (Pred Mild®)   | Allergan                      | ▪ Treatment of mild to moderate noninfectious allergic and inflammatory disorders of the lid, conjunctiva, cornea, and sclera (including chemical and thermal burns) |
| prednisolone sodium phosphate             | Valeant/Bausch               | ▪ Treatment of inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe  
▪ Corneal injury                           |

*Authorized generic
### FDA-Approved Indications (continued)

<table>
<thead>
<tr>
<th>Drug</th>
<th>Manufacturer</th>
<th>Indication(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Corticosteroids – Implants, Inserts, or Injections</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>dexamethasone suspension</td>
<td>Icon/EyePoint</td>
<td>• Treatment of post-operative inflammation</td>
</tr>
<tr>
<td>(Dexycu®)17</td>
<td></td>
<td></td>
</tr>
<tr>
<td>dexamethasone implant</td>
<td>Allergan</td>
<td>• Treatment of macular edema following branch retinal vein occlusion (BRVO) or central retinal vein occlusion (CRVO)</td>
</tr>
<tr>
<td>(Ozurdex®)18</td>
<td></td>
<td>• Treatment of non-infectious uveitis affecting the posterior segment of the eye</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Treatment of diabetic macular edema</td>
</tr>
<tr>
<td>dexamethasone insert</td>
<td>Ocular Therapeutix</td>
<td>• Treatment of ocular pain and inflammation following ophthalmic surgery</td>
</tr>
<tr>
<td>(Dextenza®)19</td>
<td></td>
<td></td>
</tr>
<tr>
<td>fluocinolone 0.18 mg</td>
<td>EyePoint</td>
<td>• Treatment of chronic non-infectious uveitis affecting the posterior segment of the eye</td>
</tr>
<tr>
<td>(Yutiq™)20</td>
<td></td>
<td></td>
</tr>
<tr>
<td>fluocinolone 0.19 mg</td>
<td>Alimera</td>
<td>• Treatment of diabetic macular edema in patients who have been previously treated with a course of corticosteroids and did not have a clinically significant rise in intraocular pressure</td>
</tr>
<tr>
<td>(Iluvien®)21</td>
<td></td>
<td></td>
</tr>
<tr>
<td>fluocinolone 0.59 mg</td>
<td>Valeant/Bausch</td>
<td>• Treatment of chronic non-infectious uveitis affecting the posterior segment of the eye</td>
</tr>
<tr>
<td>(Retisert®)22</td>
<td></td>
<td></td>
</tr>
<tr>
<td>triamcinolone acetonide</td>
<td>Alcon/Novartis</td>
<td>• Treatment of sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids</td>
</tr>
<tr>
<td>(Triesence®)23</td>
<td></td>
<td>• Visualization during vitrectomy</td>
</tr>
<tr>
<td><strong>NSAIDs</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>bromfenac 0.07%</td>
<td>Valeant/Bausch</td>
<td>• Treatment of post-operative inflammation and reduction of ocular pain secondary to cataract extraction/surgery†</td>
</tr>
<tr>
<td>(Prolensa™)24</td>
<td></td>
<td></td>
</tr>
<tr>
<td>bromfenac 0.075%</td>
<td>Sun</td>
<td>• Treatment of post-operative inflammation secondary to cataract extraction</td>
</tr>
<tr>
<td>(Bromsite™)25</td>
<td></td>
<td>• Temporary relief of pain and photophobia in patients undergoing corneal refractive surgery</td>
</tr>
<tr>
<td>bromfenac 0.09%</td>
<td>generic</td>
<td>• Treatment of post-operative inflammation secondary to cataract extraction</td>
</tr>
<tr>
<td>diclofenac27</td>
<td>generic</td>
<td>• Inhibition of intraoperative miosis</td>
</tr>
<tr>
<td>flurbiprofen28</td>
<td>generic</td>
<td>• Reduction of ocular pain, burning, and stinging after corneal refractive surgery</td>
</tr>
<tr>
<td>ketorolac 0.4% (Acular LS®)</td>
<td>Allergan, Pacific/Greenstone*</td>
<td>• Treatment of pain and inflammation following cataract surgery</td>
</tr>
<tr>
<td>(Acuvail®)30</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ketorolac 0.5% (Acular®)</td>
<td>Allergan</td>
<td>• Treatment of inflammation following cataract surgery‡</td>
</tr>
<tr>
<td>nepafenac (Iлевро™, Nevana®)</td>
<td>Alcon/Novartis</td>
<td>• Treatment of pain and inflammation associated with cataract surgery</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* Authorized generic  
† Bromsite is approved for the treatment of post-operative inflammation and prevention of ocular pain in patients undergoing cataract surgery.  
‡ Ketorolac 0.5% ophthalmic solution (Acular®) is also indicated for the temporary relief from ocular itching related to seasonal allergic conjunctivitis.  
§ Alcon has discontinued manufacture of Vexol® (rimexolone) for the treatment of postoperative inflammation following ocular surgery and in the treatment of anterior uveitis.
Loteprednol ophthalmic suspension 0.2% (Alrex®) is indicated for the temporary relief of signs and symptoms of seasonal allergic conjunctivitis and is not included in this therapeutic class review.

**OVERVIEW**

Uveitis is an inflammation of the middle layer of the eye or uvea, consisting of the iris, ciliary body, and choroid. Uveitis may be caused by eye trauma, secondary to autoimmune diseases or infection, or may be idiopathic in nature. It may present as acute, chronic, or recurrent attacks, with unilateral pain or photophobia. Aqueous cells and flare, due to cellular infiltration and protein exudation into the anterior chamber, are seen as spots and haze on slit-beam examination; both are signs of ocular inflammation. If left untreated, uveitis can lead to glaucoma, cataract, or retinal edema and ultimately loss of vision. Initial treatment for uveitis typically includes ophthalmic corticosteroids to reduce pain and inflammation.

Temporal arteritis, affecting the superficial temporal arteries, is a systemic inflammatory vasculitis of unknown etiology that occurs in older individuals and can result in systemic, neurologic, and ophthalmologic complications. Permanently visual impairment is estimated in up to 20% of patients with the condition. Timely initiation of therapy may prevent irreversible damage, including blindness. The mainstay of therapy includes corticosteroids, which are typically prescribed for up to 2 years.

To ensure its transparency, the cornea is maintained in a dehydrated state by the pumping action of the endothelial cells controlled by Na+/K+-ATPase. Damage to the corneal endothelium may result in increased corneal thickness and ultimately corneal decompensation and loss of vision. Ophthalmic surgery, such as cataract extraction, generally results in moderate damage to the endothelium and a transient increase in corneal thickness. Endothelial cell count (density) and corneal thickness measurements are used to assess the degree of endothelial damage.

Ophthalmic anti-inflammatories, including corticosteroids and non-steroidal anti-inflammatory drugs (NSAIDs), are used to treat inflammatory conditions of the eye, including those due to trauma and surgery.

Topical corticosteroids are available in drops, gels, and ointments and are the standard of care for treating ophthalmic inflammation. Ophthalmic corticosteroids can, however, lead to side effects, such as increased intraocular pressure (IOP), cataract development, and increased risk of ocular infection.

Ophthalmic NSAIDs are primarily used during and after ophthalmic surgery. These agents reduce inflammation in the cornea and conjunctiva and help maintain papillary dilatation during surgery. Ophthalmic NSAIDs are used to control inflammation during surgery and in the first few days following surgery. Treatment with ophthalmic NSAIDs is not associated with the undesirable side effects as the ophthalmic corticosteroids as listed above. The American Academy of Ophthalmology (AAO) reports that post-operative topical regimens following cataract surgery vary among practitioners. There are no controlled studies establishing optimal regimens for the use of various topical agents, including topical corticosteroids and NSAIDs, following cataract surgery. The American Optometric Association (AOA) state that treatment with an ophthalmic topical steroid for a week before cataract surgery and an ophthalmic topical anti-inflammatory agent after surgery may provide benefit. Elevation intraocular pressure (IOP) is typically transient and may develop due to a variety of reasons during the early post-operative period (1 to 14 days) after cataract surgery. Ophthalmic corticosteroids may suppress inflammation of the trabecular meshwork and in turn decrease IOP. In patients with increased IOP in the late post-operative period and taking ophthalmic steroids, steroid response should
be suspected, which is more common in patients with glaucoma or a family history of glaucoma. The degree of response may depend on the specific corticosteroid, its dose, and duration of use. It may take several weeks for the response to occur. If the eye is quiet and the IOP is elevated, the steroid can be discontinued or quickly tapered or an alternative steroid, such as fluorometholone which has a lower risk of causing a steroid response, or a topical nonsteroidal anti-inflammatory (NSAID) may be considered.

Several ophthalmic corticosteroids that are administered via injection or implantation are approved by the Food and Drug Administration (FDA) to treat inflammatory conditions of the eye that are not related to injury or surgery, such as uveitis and macular edema. Diabetic macular edema (DME) is a microvascular complication of diabetes and is a leading cause of visual impairment and blindness in diabetic patients. DME is a progression of diabetic retinopathy and is caused by leakage of dilated capillaries and microaneurysms in the macular area. Corticosteroid implants, inserts, and injections are administered by a licensed healthcare professional under aseptic conditions. As with the topically-applied ophthalmic products, these agents are associated with side effects including, cataract formation and elevated IOP. Injection-related side effects include retinal detachment, vitreous hemorrhage, bacterial endophthalmitis, and sterile endophthalmitis.

**PHARMACOLOGY**

Topical corticosteroids exert an anti-inflammatory action. Aspects of the inflammatory process, such as edema, fibrin deposition, capillary dilation, leukocyte migration, capillary proliferation, deposition of collagen, scar formation, and fibroblastic proliferation, are suppressed. Topical corticosteroids are effective in acute inflammatory conditions of the conjunctiva, sclera, cornea, lids, iris, and anterior segment of the globe, as well as in ocular allergic conditions. In ocular disease, route of administration depends on the site and extent of the condition being treated.

Ophthalmic NSAIDs have analgesic and anti-inflammatory activity. The mechanism of action is thought to be through the inhibition of cyclooxygenase enzymes, which are essential in prostaglandin production. Prostaglandins disrupt the blood-aqueous humor barrier, produce vasodilation, and increase vascular permeability, leukocytosis, and IOP.

During vitrectomy, dispersal of the water-insoluble triamcinolone acetonide (Triesence) particles within the vitreous chamber provides contrast to the transparent vitreous humor and membranes.

**PHARMACOKINETICS**

Highly potent corticosteroids include dexamethasone acetate, difluprednate, prednisolone acetate, and prednisolone phosphate; moderate potency steroids are dexamethasone phosphate, and fluorometholone acetate. The efficacy of a topical corticosteroid is based on potency, vehicle, drug concentration, duration of action, contact time, and ocular penetration. Most topically-applied corticosteroids penetrate the eye via the cornea. In general, acetate and alcohol forms are more lipophilic and lead to longer contact time and better penetration due to the lipid nature of the cornea, while the phosphate form is more hydrophilic and leads to decreased corneal penetration. In addition, presence of intraocular inflammation may result in increased absorption.
The duration of effect of dexamethasone intravitreal implant (Ozurdex) lasts approximately 1 to 3 months. The fluocinolone acetonide intravitreal implants are designed to deliver drug over approximately 30 months (Retisert) and 36 months (Iluvien, Yutiq). Dexamethasone intraocular suspension (Dexycu) is a biodegradable extended-release formulation given as a single injection into the posterior chamber of the eye at the conclusion of surgery. Dexamethasone insert (Dextenza) is inserted in the lower lacrimal punctum and into the canaliculus, is resorbable, and releases dexamethasone for up to 30 days following insertion.

Intravitreal administration allows a corticosteroid dose to be delivered over a prolonged period of time and allows the dose to bypass the blood–retinal barrier.08

Due to the topical nature of this drug class, systemic absorption for most products is below detectable levels. Ketorolac (Acular, Acular LS, Acuvail) does achieve measurable systemic levels, but there is no clinical impact.10,11 Nepafenac (Ilevro, Nevanac) is a prodrug that is metabolized via ocular tissue hydrolases to the active NSAID, amfenac.12 Low systemic levels of nepafenac and amfenac have been observed after topical administration to the eye. Nepafenac has been shown to penetrate the cornea more rapidly and provides more complete (80% versus 50%) and longer lasting inhibition of prostaglandin synthesis (> 6 hours versus 3 hours) and vascular permeability (8 hours versus 4 hours) than diclofenac.13,14 After topical instillation, systemic levels of bromfenac (generic, Prolensa, Bromsite), diclofenac, and loteprednol 1% suspension (Inveltys) remain below the level of detection; limited (< 1 ng/mL) systemic absorption occurs with loteprednol 0.5% suspension (Lotemax) following administration of 1 drop.15,16 The systemic exposure following topical administration of loteprednol 0.5% gel (Lotemax) has not been studied in humans; loteprednol 0.38% gel (Lotemax SM) achieves minimal (< 0.2 ng/mL) systemic absorption following topical administration for up to 15 days.17,18 Loteprednol 0.38% gel (Lotemax SM) is formulated using submicron-sized drug particles, which increases the surface area exposed to tears. This formulation exhibits improved drug dissolution and penetration into the aqueous humor compared with micronized loteprednol 0.5% gel (Lotemax).19

**CONTRAINDICATIONS/WARNINGS**20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,149,150,151

Ophthalmic corticosteroids, including dexamethasone (Ozurdex, Dextenza) and fluocinonide (Iluvien, Retisert, Yutiq) intravitreal implants/inserts, are contraindicated in patients with viral (epithelial herpes simplex keratitis, vaccinia, varicella), mycobacterial, or fungal infections of the eye. Dexamethasone (Maxidex) is also contraindicated in acute, untreated bacterial infections, and dexamethasone (Dextenza) is also contraindicated in patients with dacryocystitis. The labels for dexamethasone and triamcinolone intravitreal suspension (Dexycu and Triesence) contain warnings for the use of corticosteroids in general and the risk of infection due to fungi or viruses; it should be used with caution in patients with ocular herpes simplex and should not be used in those with active infection. Triamcinolone is contraindicated in patients with systemic fungal infections.

Dexamethasone intravitreal implant (Ozurdex) and fluocinonide implant (Iluvien) are contraindicated in patients with glaucoma who have cup to disc ratios of greater than 0.8; a cup to disc ratio greater than 0.6 suggests glaucoma.152 Dexamethasone intravitreal implant is also contraindicated in patients with a rupture of the posterior lens capsule. The fluocinonide implant, Yutiq, does not carry a contraindication for glaucoma; however, its labeling does warn of development of cataracts, increased intraocular pressure, and glaucoma.
Prolonged use of ophthalmic corticosteroids, including intravitreal agents, may cause ocular hypertension and/or glaucoma, defects in visual acuity and fields of vision, posterior subcapsular cataract formation, and secondary ocular infections (bacterial, fungal, viral). Perforations have occurred in patients with thinning of the cornea or sclera. If used for 10 days or more, intraocular pressure should be monitored. Use ophthalmic corticosteroids with caution in patients with glaucoma.

The products in this review are contraindicated in patients with known hypersensitivity to any component of the product. Bromfenac (Prolensa) contains sodium sulfite which may cause allergic-type reactions, including anaphylactic symptoms and life-threatening or less severe asthmatic episodes, particularly in those with asthma. As with all NSAIDs, cross-hypersensitivity in patients with aspirin and other NSAID-hypersensitivities is possible; caution should be used in such patients. There have been reports of bronchospasm or exacerbation of asthma associated with the use of ketorolac tromethamine ophthalmic solution in patients who either have a known hypersensitivity to aspirin/NSAID or a past medical history of asthma.

The use of corticosteroids in phakic individuals may promote the development of posterior subcapsular cataracts.

Surgical complications have been associated with implant, insert, and injectable products. Intravitreally administered corticosteroid implants and suspensions have been associated with endophthalmitis, eye inflammation, increased IOP, and retinal detachments. Following implantation of fluocinolone (Iluvien, Retisert, Yutiq), patients may experience an immediate and temporary decrease in visual acuity lasting 1 to 4 weeks post-operatively. Intravitreal implants may migrate to the anterior chamber if the posterior lens capsule is not intact; the fluocinolone implant (Retisert) has been associated with separation of implant components.

Refractive stability of patients undergoing corneal refractive procedures and treatment with diclofenac usage has not been well established. There have been reports that ophthalmic NSAIDs may cause increased bleeding of ocular tissues when used in this setting; therefore, patients should be monitored for a year following use in this setting. Use with caution in patients at increased risk of bleeding.

In March 2016, the FDA warned the public that eye drop bottles that have loose plastic safety seals or tamper-evident rings (also known as a collar or band) below the bottle cap may cause eye injuries during administration if the seal/ring falls onto the eye. The FDA has required a change in the packaging design for all affected products.

NSAIDs may cause keratitis. In some patients, continued use of topical NSAIDs may result in epithelial breakdown, corneal thinning, corneal erosion, corneal ulceration, or corneal perforation. These events may be sight-threatening. Patients with evidence of corneal epithelial breakdown should discontinue use of topical NSAIDs immediately and should be closely monitored. Patients who might be at risk for complications include those with complicated ocular surgeries, corneal denervation, corneal epithelial defects, diabetes mellitus, ocular surface diseases (e.g., dry eye syndrome), rheumatoid arthritis, or repeat ocular surgeries within a short period of time. Using ophthalmic NSAIDs beyond the 14 days may increase a patient’s risk of severe corneal adverse events.

Topical NSAIDs, topical corticosteroids, and select intraocular corticosteroids (Dexycu, Dextenza) may slow or delay healing. Concomitant use of topical NSAIDs and topical steroids may increase this risk.

Bromfenac (generic, Prolensa, Bromsite), ketorolac (Acular, Acular LS, Acuvail), nepafenac (Ilevro, Nevanac), and prednisolone acetate suspension (Pred Forte, Pred Mild) should not be administered
while wearing contact lenses. Except for the use of a bandage hydrogel soft contact lens during the first 3 days following refractive surgery, diclofenac 0.1% solution should not be used by patients currently wearing soft contact lenses. Contact lenses should be removed prior to administering loteprednol 1% suspension (Inveltys) and may be reinserted 15 minutes following dose; labeling for loteprednol 0.5% products (Lotemax) instruct against wearing of contact lenses during treatment course. Labeling for loteprednol 0.38% gel (Lotemax SM) instructs against wearing of contact lenses when the eyes are inflamed.

Precautions for triamcinolone intravitreal suspension (Triesence) include elevated blood pressure, salt and water retention, hypokalemia, gastrointestinal perforation, behavioral and mood disturbances, decreased bone density, and weight gain.

Use of the same bottle for both eyes is not recommended with topical eye drops that are used in association with surgery.

**DRUG INTERACTIONS**

Due to the topical nature of these anti-inflammatory agents, drug interaction studies have not been systematically performed. Nepafenac (Nevanac) has been investigated for potential impact on the cytochrome P450 system; no potential impact was identified.

When ophthalmic medications need to be used concurrently, they should be administered at least 5 minutes apart.

**ADVERSE EFFECTS**

Adverse effects are reported as a percentage. Adverse effects data are obtained from prescribing information and are not meant to be comparative or all inclusive. nr = not reported.

<table>
<thead>
<tr>
<th>Drug</th>
<th>Transient burning/stinging</th>
<th>Ocular irritation</th>
<th>Corneal edema</th>
<th>Vision change</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dexamethasone (Maxidex)</td>
<td>nr</td>
<td>1</td>
<td>nr</td>
<td>&gt; 1</td>
</tr>
<tr>
<td>Dexamethasone sodium phosphate</td>
<td>reported</td>
<td>reported</td>
<td>nr</td>
<td>reported</td>
</tr>
<tr>
<td>Difluprednate (Durezol)</td>
<td>nr</td>
<td>1-5</td>
<td>2-5</td>
<td>1-5</td>
</tr>
<tr>
<td>Fluorometholone (FML)</td>
<td>reported</td>
<td>reported</td>
<td>nr</td>
<td>reported</td>
</tr>
<tr>
<td>Fluorometholone (FML Forte)</td>
<td>reported</td>
<td>reported</td>
<td>nr</td>
<td>reported</td>
</tr>
<tr>
<td>Fluorometholone (FML S.O.P.)</td>
<td>nr</td>
<td>reported</td>
<td>nr</td>
<td>nr</td>
</tr>
<tr>
<td>Fluorometholone acetate (Flarex)</td>
<td>nr</td>
<td>nr</td>
<td>nr</td>
<td>reported</td>
</tr>
</tbody>
</table>
**Adverse Effects (continued)**

<table>
<thead>
<tr>
<th>Drug</th>
<th>Transient burning/stinging</th>
<th>Ocular irritation</th>
<th>Corneal edema</th>
<th>Vision change</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Corticosteroids (continued)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>loteprednol gel (Lotemax)</td>
<td>nr</td>
<td>nr</td>
<td>nr</td>
<td>nr</td>
</tr>
<tr>
<td>loteprednol gel (Lotemax SM)</td>
<td>nr</td>
<td>nr</td>
<td>nr</td>
<td>nr</td>
</tr>
<tr>
<td>loteprednol ointment (Lotemax)</td>
<td>nr</td>
<td>nr</td>
<td>4-5</td>
<td>nr</td>
</tr>
<tr>
<td>loteprednol suspension (Inveltys)</td>
<td>nr</td>
<td>nr</td>
<td>nr</td>
<td>nr</td>
</tr>
<tr>
<td>loteprednol suspension (Lotemax)</td>
<td>5-15</td>
<td>&lt; 5</td>
<td>&lt; 5</td>
<td>5-15</td>
</tr>
<tr>
<td>prednisolone acetate (Omnipred, Pred Forte)</td>
<td>reported</td>
<td>reported</td>
<td>nr</td>
<td>reported – blurry vision (Pred Forte)</td>
</tr>
<tr>
<td>prednisolone acetate (Pred Mild)</td>
<td>reported</td>
<td>nr</td>
<td>nr</td>
<td>reported</td>
</tr>
<tr>
<td>prednisolone sodium phosphate</td>
<td>nr</td>
<td>nr</td>
<td>nr</td>
<td>reported</td>
</tr>
</tbody>
</table>

**Corticosteroids – Implants, Inserts, or Injections**

<table>
<thead>
<tr>
<th>Drug</th>
<th>Transient burning/stinging</th>
<th>Ocular irritation</th>
<th>Corneal edema</th>
<th>Vision change</th>
</tr>
</thead>
<tbody>
<tr>
<td>dexamethasone suspension (Dexycu)</td>
<td>nr</td>
<td>nr</td>
<td>5-15</td>
<td>1-5</td>
</tr>
<tr>
<td>dexamethasone implant (Ozurdex)</td>
<td>nr</td>
<td>7</td>
<td>nr</td>
<td>nr</td>
</tr>
<tr>
<td>dexamethasone insert (Dextenza)</td>
<td>nr</td>
<td>nr</td>
<td>1</td>
<td>2</td>
</tr>
<tr>
<td>fluocinolone (Yutiq)</td>
<td>nr</td>
<td>1</td>
<td>nr</td>
<td>15</td>
</tr>
<tr>
<td>fluocinolone (Iluvien)</td>
<td>nr</td>
<td>8</td>
<td>4</td>
<td>5-29</td>
</tr>
<tr>
<td>fluocinolone (Retisert)</td>
<td>nr</td>
<td>10-40</td>
<td>50-90</td>
<td>10-40</td>
</tr>
<tr>
<td>triamcinolone acetonide (Triesence)</td>
<td>nr</td>
<td>&lt; 2</td>
<td>nr</td>
<td>&lt; 2</td>
</tr>
</tbody>
</table>

Adverse effects are reported as a percentage. Adverse effects data are obtained from prescribing information and are not meant to be comparative or all inclusive. nr = not reported.
# Ophthalmic Anti-Inflammatories Review – July 2019

## Adverse Effects (continued)

<table>
<thead>
<tr>
<th>Drug</th>
<th>Transient burning/stinging</th>
<th>Ocular irritation</th>
<th>Corneal edema</th>
<th>Vision change</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>NSAIDs</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>bromfenac 0.07% (Prolensa)</td>
<td>nr</td>
<td>nr</td>
<td>nr</td>
<td>3-8</td>
</tr>
<tr>
<td>bromfenac 0.075% (Bromsite)</td>
<td>nr</td>
<td>1-8</td>
<td>nr</td>
<td>Nr</td>
</tr>
<tr>
<td>bromfenac 0.09%</td>
<td>2-7</td>
<td>2-7</td>
<td>nr</td>
<td>Nr</td>
</tr>
<tr>
<td>diclofenac</td>
<td>15</td>
<td>&lt; 5</td>
<td>&lt; 5</td>
<td>&lt; 5</td>
</tr>
<tr>
<td>flurbiprofen</td>
<td>reported</td>
<td>reported</td>
<td>nr</td>
<td>Nr</td>
</tr>
<tr>
<td>ketorolac (Acular, Acular LS)</td>
<td>20-40</td>
<td>1-10</td>
<td>1-10</td>
<td>Nr</td>
</tr>
<tr>
<td>ketorolac (Acuvail)</td>
<td>nr</td>
<td>1-6</td>
<td>1-6</td>
<td>1-6</td>
</tr>
<tr>
<td>nepafenac (Ilevo, Nevanac)</td>
<td>reported</td>
<td>1-5</td>
<td>1-5</td>
<td>5-10</td>
</tr>
</tbody>
</table>

Adverse effects are reported as a percentage. Adverse effects data are obtained from prescribing information and are not meant to be comparative or all inclusive. nr = not reported.

In clinical trials, ocular discomfort was reported in approximately 10% of patients treated with dexamethasone (Maxidex).

The most common ocular adverse event reported in clinical studies for loteprednol ointment was anterior chamber inflammation at a rate of approximately 25%. In studies with loteprednol 0.5% gel (Lotemax), this was reported in 5% of subjects. In the clinical trial with loteprednol 0.38% gel (Lotemax SM), there were no adverse reactions that occurred with a greater incidence than placebo.219

Benzalkonium chloride is a preservative used in many ophthalmic preparations; however, it can cause a dose- and duration-dependent breakdown of the corneal epithelium and increased absorption. The following products contain benzalkonium chloride: bromfenac (Bromsite, Prolensa), dexamethasone (Maxidex), dexamethasone sodium phosphate, fluorometholone (FML, FML Forte), fluorometholone acetate (Flarex), loteprednol (Inveltys, Lotemax suspension and gel, Lotemax SM gel), ketorolac (Acular, Acular LS), nepafenac (Ilevo, Nevanac), prednisolone acetate (Omnipred, Pred Forte, Pred Mild), and prednisolone sodium phosphate. Flurbiprofen contains thimerosal, which can cause allergic contact conjunctivitis.220 Sorbic acid, which may cause less damage and irritation to the ocular surface, is the preservative in difluprednate (Durezol).221 Fluorometholone (FML S.O.P.) uses phenylmercuric acetate; ocular side effects are rare, but mercurialentis (deposition of pigment on the lens) has been reported.222 Ketaorolac (Acuvail) does not contain any preservative.

The most common adverse reactions following use of bromfenac 0.07% (Prolensa), reported in 3% to 8% of patients, include anterior chamber inflammation, foreign body sensation, eye pain, and photophobia. The most common adverse reactions following use of bromfenac 0.075% (Bromsite), reported in 1% to 8% of patients, include anterior chamber inflammation, headache, vitreous floaters, iritis, eye pain, and ocular hypertension.
The most commonly reported adverse reactions with dexamethasone intraocular suspension (Dexycu) occurred in 5% to 15% of subjects and included increases in intraocular pressure, corneal edema, and iritis. Other ocular adverse effects reported in 1% to 5% of patients included blepharitis, corneal endothelial cell loss, cystoid macular edema, dry eye, eye pain, foreign body sensation, ocular inflammation, photophobia, posterior capsule opacification, reduced visual acuity, vitreous floaters, and vitreous detachment.

The most commonly reported adverse reactions not described above with dexamethasone insert (Dextenza) occurred in 1% to 6% of subjects and included headache, elevated intraocular pressure, anterior chamber inflammation, iritis, cystoid macular edema, eye pain, and conjunctival hyperemia.

The most common adverse effects reported with fluocinonide intravitreal implant (Iluvien) are cataracts (82%) and myodesopsia (floaters; 21%). The most common adverse effects (>20%) reported with fluocinonide intravitreal implant (Yutiq) is cataracts (56%). With fluocinonide intravitreal implant (Retisert) and triamcinolone suspension (Triesence) the most common adverse effects are cataracts and increased ocular pressure; and with dexamethasone implant (Ozurdex) are increased ocular pressure (25%) and conjunctival hemorrhage (22%).

Results from clinical studies indicate that ophthalmic NSAIDs have no significant effect on IOP; however, after cataract surgery, changes in IOP may occur. In clinical studies with diclofenac, elevated IOP following cataract surgery was reported in approximately 15% of patients undergoing cataract surgery. Studies reported increased ocular pressure following cataract surgery in 5% to 10% of patients treated with nepafenac 0.1% suspension (Nevanac). In the MEAD clinical study, increased IOP by at least 10 mm Hg was reported in 27.7% of patients with diabetic macular edema who were treated with dexamethasone 0.7 mg implant (Ozurdex).223

In a 3-month, double-masked trial, a similar safety profile was observed for difluprednate (Durezol) and prednisolone acetate ophthalmic suspension 1%, in 79 pediatric patients, 0 to 3 years of age, in the treatment of inflammation following cataract surgery.224

Secondary ocular infections (e.g., bacterial, fungal, viral) have occurred with prednisolone acetate ophthalmic suspension 1%, in 79 pediatric patients, 0 to 3 years of age, in the treatment of inflammation following cataract surgery.224

Safety and efficacy of fluocinolone (Iluvien, Yutiq), dexamethasone implant (Ozurdex), dexamethasone insert (Dextenza), and dexamethasone intraocular suspension (Dexycu) have not been established in pediatric patients, while safety and effectiveness of fluocinolone intravitreal implant (Retisert) have not been established in patients younger than 12 years. The labeling for triamcinolone intravitreal suspension (Triesence) states that safety and efficacy of corticosteroids is similar in pediatric and adult populations.

The safety and effectiveness of dexamethasone 0.1% (Maxidex) and loteprednol 0.5% gel (Lotemax) have been established in pediatrics of all ages; their use in this population is supported by controlled
studies in adults; **efficacy trials of loteprednol gel also support its use in patients from birth to 11 years of age.**

Fluorometholone (FML, FML Forte, FML S.O.P.) has been studied in children ages 2 years and older.\(^{257}\) The safety and efficacy of other corticosteroid products in this class have not been studied, but dexamethasome drops and prednisolone are reportedly safe in children, in general.\(^{258}\)

Safety and effectiveness in pediatric patients have not been established in children for bromfenac (generic, Prolensa, Bromsite), diclofenac, flurbiprofen sodium, ketorolac tromethamine 0.45% solution (Acuvail), loteprednol ointment and suspension (Inveltys, Lotemax), and **loteprednol 0.38% gel (Lotemax SM).**

Nepafenac (Iлевро, Nevanac) has not been studied in children less than 10 years of age.

Safety and efficacy have not been established for ketorolac 0.4% (Acular LS) in children younger than age 3 years and for ketorolac 0.5% (Acular) in children younger than 2 years.

**Pregnancy**

With the exception of triamcinolone (Triesence), which is Pregnancy Category D, agents in this class assigned a Pregnancy Category are Pregnancy Category C. Due to the known effects of NSAIDs and the prostaglandin biosynthesis-inhibiting drugs on the fetal cardiovascular system, including the closure of ductus arteriosus, the use of many of these ophthalmic NSAIDs during late pregnancy should be avoided. Bromfenac (Bromsite) has not been assigned a Pregnancy Category based on the Pregnancy and Lactation Labeling Rule (PLLR). There are no adequate and well-controlled studies of bromfenac 0.075%, dexamethasone intraocular suspension (Dexycu), dexamethasone ocular insert (Dextenza), or **fluocinolone intravitreal implant (Yutiq)** in pregnant women to inform any drug associated risks. Bromfenac’s risks are expected to be similar to other ocular NSAIDs with minimal systemic absorption, as described above. The labeling for bromfenac ophthalmic solution 0.07% (Prolensa), dexamethasone 0.1% (Maxidex), dexamethasone intravitreal implant (Ozurdex), loteprednol gel (Lotemax, Lotemax SM), ketorolac 0.4% solution (Acular LS), and prednisolone acetate suspension (Pred Forte, Pred Mild) have been updated to conform to the PLLR; studies in pregnant women are lacking and these agents should be used during pregnancy only if potential benefit justifies the potential risk to the fetus.

**Labeling for loteprednol 1% suspension (Inveltys), states that it is not absorbed systemically after topical ophthalmic administration, therefore, fetal exposure is not expected.**
# Ophthalmic Anti-Inflammatories Review – July 2019

**Corticosteroids**

<table>
<thead>
<tr>
<th>Drug</th>
<th>Dosage</th>
<th>Availability</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Dexamethasone 0.1% suspension (Maxidex)</strong></td>
<td>Apply 1 to 2 drops to the conjunctival sac of the affected eye(s) every 4 to 6 hours; in severe disease, may administer drops hourly, tapering to discontinuation as the inflammation subsides</td>
<td>5 mL</td>
</tr>
<tr>
<td><strong>Dexamethasone sodium phosphate 0.1% solution</strong></td>
<td>Apply 1 to 2 drops to the conjunctival sac of the affected eye(s) every hour during the day and every 2 hours at night; reduce frequency to every 4 hours once a favorable response occurs</td>
<td>5 mL</td>
</tr>
<tr>
<td><strong>Difluprednate 0.05% emulsion (Durezol)</strong></td>
<td><strong>Inflammation and pain with ocular surgery:</strong> Apply 1 drop to the conjunctival sac of the affected eye(s) 4 times daily beginning 24 hours after surgery and continuing for 2 weeks post-op, then twice daily for another week, then taper based on response. <strong>Endogenous anterior uveitis:</strong> Apply 1 drop to the conjunctival sac of the affected eye 4 times daily for 14 days followed by tapering, as clinically indicated</td>
<td>5 mL</td>
</tr>
<tr>
<td><em><em>Fluorometholone 0.1% suspension</em> (FML)</em>*</td>
<td>Apply 1 drop to the conjunctival sac of the affected eye(s) 2 to 4 times daily (may be used every 4 hours during initial 24 to 48 hours)</td>
<td>5 mL, 10 mL</td>
</tr>
<tr>
<td><strong>Fluorometholone 0.25% suspension (FML Forte)</strong></td>
<td>Apply 1 drop to the conjunctival sac of the affected eye(s) 2 to 4 times daily (may be used every 4 hours during initial 24 to 48 hours)</td>
<td>5 mL, 10 mL</td>
</tr>
<tr>
<td><strong>Fluorometholone 0.1% ointment (FML S.O.P.)</strong></td>
<td>Apply half-inch ribbon to the conjunctival sac of the affected eye(s) 1 to 3 times daily (may be used every 4 hours during initial 24 to 48 hours)</td>
<td>3.5 g tube</td>
</tr>
<tr>
<td><strong>Fluorometholone acetate 0.1% suspension (Flarex)</strong></td>
<td>Apply 1 to 2 drops to the conjunctival sac of the affected eye(s) 4 times daily (may be used as 2 drops every 2 hours during initial 24 to 48 hours)</td>
<td>5 mL</td>
</tr>
<tr>
<td><strong>Loteprednol 1% suspension (Inveltys)</strong></td>
<td>Apply 1 to 2 drops into the affected eye twice daily beginning the day after surgery and continuing for 2 weeks after surgery</td>
<td>2.8 mL</td>
</tr>
<tr>
<td><strong>Loteprednol 0.5% gel (Lotemax)</strong></td>
<td>Apply 1 to 2 drops into the conjunctival sac of the affected eye(s) 4 times daily starting 24 hours after surgery and continuing for 2 weeks</td>
<td>5 g</td>
</tr>
<tr>
<td><strong>Loteprednol 0.38% gel (Lotemax SM)</strong></td>
<td>Apply 1 drop into the conjunctival sac of the affected eye(s) 3 times daily starting 24 hours after surgery and continuing for 2 weeks</td>
<td>5 g</td>
</tr>
<tr>
<td><strong>Loteprednol 0.5% ointment (Lotemax)</strong></td>
<td>Apply half-inch ribbon into the conjunctival sac of the affected eye(s) 4 times daily starting 24 hours after surgery for 2 weeks</td>
<td>3.5 g tube</td>
</tr>
<tr>
<td><strong>Loteprednol 0.5% suspension (Lotemax)</strong></td>
<td>Anti-inflammatory: Apply 1 to 2 drops 4 times daily (up to every hour during the first week, if necessary) <strong>Cataract surgery:</strong> Apply 1 to 2 drops 4 times a day starting 24 hours after surgery for 2 weeks</td>
<td>5 mL, 10 mL, 15 mL</td>
</tr>
</tbody>
</table>

* Authorized generic available
### Dosages (continued)

<table>
<thead>
<tr>
<th>Drug</th>
<th>Dosage</th>
<th>Availability</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Corticosteroids (continued)</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>prednisolone acetate 1% suspension*</td>
<td><strong>Omnipred</strong>: Apply 2 drops to the affected eye(s) 4 times daily</td>
<td>5 mL, 10 mL, 15 mL</td>
</tr>
<tr>
<td>(Omnipred, Pred Forte)</td>
<td><strong>Pred Forte</strong>: Apply 1 to 2 drops into the conjunctival sac of the</td>
<td></td>
</tr>
<tr>
<td></td>
<td>affected eye(s) 2 to 4 times daily (may increase dosing frequency</td>
<td></td>
</tr>
<tr>
<td></td>
<td>during the initial 24 to 48 hours if needed)</td>
<td></td>
</tr>
<tr>
<td>prednisolone acetate 0.12% suspension</td>
<td>Apply 1 to 2 drops to the conjunctival sac of the affected eye(s) 2</td>
<td>5 mL, 10 mL</td>
</tr>
<tr>
<td>(Pred Mild)</td>
<td>to 4 times daily (may increase dosing frequency during the initial</td>
<td></td>
</tr>
<tr>
<td></td>
<td>24 to 48 hours if needed)</td>
<td></td>
</tr>
<tr>
<td>prednisolone sodium phosphate 1% solution</td>
<td>Apply 1 to 2 drops to the conjunctival sac of the affected eye(s) every</td>
<td>10 mL</td>
</tr>
<tr>
<td></td>
<td>2 to 4 times daily (may increase dosing frequency during the initial</td>
<td></td>
</tr>
<tr>
<td></td>
<td>24 to 48 hours if needed)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Corticosteroids – Implants, Inserts, and</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>dexamethasone suspension (Dexycu)</td>
<td>Inject 0.005 mL of dexamethasone 9% (517 mcg) intraocularly into the</td>
<td>Sterile Kit</td>
</tr>
<tr>
<td></td>
<td></td>
<td>containing 1 of</td>
</tr>
<tr>
<td></td>
<td></td>
<td>each of the following:</td>
</tr>
<tr>
<td></td>
<td></td>
<td>dexamethasone 0.5 mL</td>
</tr>
<tr>
<td></td>
<td></td>
<td>vial, 1 mL syringe, syringe</td>
</tr>
<tr>
<td></td>
<td></td>
<td>guide, syringe ring, 18-</td>
</tr>
<tr>
<td></td>
<td></td>
<td>gauge needle, and 25-</td>
</tr>
<tr>
<td></td>
<td></td>
<td>gauge bent cannula</td>
</tr>
<tr>
<td>dexamethasone implant (Ozurdex)</td>
<td>Implanted intravitreally by a healthcare provider</td>
<td>0.7 mg implant</td>
</tr>
<tr>
<td>dexamethasone insert (Dextenza)</td>
<td>Inserted in the lower lacrimal punctum into the canaliculus by a</td>
<td>0.4 mg insert</td>
</tr>
<tr>
<td></td>
<td>healthcare provider</td>
<td></td>
</tr>
<tr>
<td>fluocinolone (Yutiq)</td>
<td>Surgically implanted inferior to the optic disc and posterior to the</td>
<td>0.18 mg implant</td>
</tr>
<tr>
<td></td>
<td>equator of the eye; designed to release drug over 36 months</td>
<td></td>
</tr>
<tr>
<td>fluocinolone (Iluvien)</td>
<td>Surgically implanted inferior to the optic disc and posterior to the</td>
<td>0.19 mg implant</td>
</tr>
<tr>
<td></td>
<td>equator of the eye; designed to release drug over 36 months</td>
<td></td>
</tr>
<tr>
<td>fluocinolone (Retisert)</td>
<td>Surgically implanted into posterior segment of the affected eye(s);</td>
<td>0.59 mg implant</td>
</tr>
<tr>
<td></td>
<td>designed to release drug over 30 months</td>
<td></td>
</tr>
<tr>
<td>triamcinolone acetonide (Triesence)</td>
<td>Inflammation: 4 mg intravitreally</td>
<td>40 mg/1 mL vial</td>
</tr>
<tr>
<td></td>
<td>Visualization: 1 to 4 mg intravitreally</td>
<td></td>
</tr>
</tbody>
</table>

* Authorized generic available
## Dosages (continued)

<table>
<thead>
<tr>
<th>Drug</th>
<th>Dosage</th>
<th>Availability</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>NSAIDs</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>bromfenac 0.07% solution (Prolensa)</td>
<td>Apply 1 drop once daily to affected eye(s) starting 1 day prior to surgery, continued on the day of surgery and through the first 14 days post-op</td>
<td>3 mL</td>
</tr>
<tr>
<td>bromfenac 0.075% solution (Bromsite)</td>
<td>Apply 1 drop to affected eye(s) twice daily starting 1 day prior to surgery, continued on the day of surgery and through the first 14 days post-op</td>
<td>5 mL</td>
</tr>
<tr>
<td>bromfenac 0.09% solution</td>
<td>Apply 1 drop to affected eye(s) twice daily starting 24 hours post-op for 2 weeks</td>
<td>1.7 mL</td>
</tr>
<tr>
<td>diclofenac 0.1% solution</td>
<td><strong>Cataract surgery:</strong> Apply 1 drop to affected eye(s) 4 times daily starting 24 hours post-op for 2 weeks&lt;br&gt;<strong>Refractive surgery:</strong> Apply 1 to 2 drops within 1 hour prior to surgery, then 1 to 2 drops 15 minutes post-op, then 1 to 2 drops 4 times a day for up to 3 days</td>
<td>2.5 mL, 5 mL</td>
</tr>
<tr>
<td>flurbiprofen sodium 0.03% solution</td>
<td>Beginning 2 hours before surgery, instill 1 drop to affected eye(s) every 30 minutes for a total of 4 drops</td>
<td>2.5 mL</td>
</tr>
<tr>
<td>ketorolac tromethamine 0.4% solution*</td>
<td>Apply 1 drop to affected eye(s) 4 times a day for up to 4 days as needed for burning or stinging following refractive surgery</td>
<td>5 mL</td>
</tr>
<tr>
<td>ketorolac tromethamine 0.45% solution (Acuval)</td>
<td>Apply 1 drop to affected eye(s) twice daily beginning 1 day prior to surgery and continuing through the first 2 weeks post-op</td>
<td>0.4 mL single-use vials</td>
</tr>
</tbody>
</table>
| ketorolac tromethamine 0.5% solution (Acular)| For cataracts: 1 drop 4 times per day beginning 24 hours after surgery and continuing through the first 2 weeks of the post-operative period  
For allergic conjunctivitis: 1 drop to affected eye(s) 4 times a day | 5 mL, 3 mL, 10 mL (generic only) |
| nepafenac 0.3% suspension (Ilevro)   | Apply 1 drop to affected eye(s) once daily beginning 1 day prior to surgery; continue on the day of surgery, and through the first 2 weeks post-op; Administer an additional drop 30 to 120 minutes prior to surgery | 1.7 mL, 3 mL |
| nepafenac 0.1% suspension (Nevanac)  | Apply 1 drop to affected eye(s) 3 times daily beginning 1 day prior to surgery; continue on the day of surgery, and through the first 2 weeks post-op                                                                 | 3 mL         |

* Authorized generic available
CLINICAL TRIALS

Articles were identified through searches performed on PubMed and review of information sent by manufacturers. Search strategy included the ophthalmic use of all drugs in this class. Randomized, controlled, comparative trials for ophthalmic FDA-approved indications are considered the most relevant in this category. Studies included for analysis in the review were published in English, performed with human participants, and randomly allocated participants to comparison groups. In addition, studies must contain clearly stated, predetermined outcome measure(s) of known or probable clinical importance, use data analysis techniques consistent with the study question and include follow-up (endpoint assessment) of at least 80% of participants entering the investigation. Despite some inherent bias found in all studies including those sponsored and/or funded by pharmaceutical manufacturers, the studies in this therapeutic class review were determined to have results or conclusions that do not suggest systematic error in their experimental study design. While the potential influence of manufacturer sponsorship and/or funding must be considered, the studies in this review have also been evaluated for validity and importance. Several studies were performed in the perioperative setting which is not applicable to the outpatient utilization. These studies were excluded from this review.

There are no published comparative trials of ophthalmic corticosteroid implants, inserts, or injectable agents.

Topical Corticosteroids

difluprednate 0.05% (Durezol) versus prednisolone acetate 1%

In a multicenter, randomized, contralateral-eye, double-masked trial, the effects of difluprednate 0.05% and prednisolone acetate 1% on corneal thickness and visual acuity after cataract surgery were compared on 52 patients (104 eyes) that underwent bilateral phacoemulsification. For each patient, the first eye randomly received difluprednate 0.05% or prednisolone acetate 1%; the other eye received the alternative. Before surgery, 7 doses were administered over 2 hours; 3 additional doses were given after surgery, before discharge. For the remainder of the day, corticosteroids were administered every 2 hours, then 4 times daily during week-1, and twice daily during week-2. On day-1 after surgery, corneal thickness was 33 μm less in difluprednate-treated eyes (p=0.026), uncorrected and best corrected visual acuity were significantly better with difluprednate than prednisolone by 0.093 logMAR lines (p=0.041) and 0.134 logMAR lines (p<0.001), respectively. Endothelial cell density was 195.52 cells/mm² higher in difluprednate-treated eyes at day 30 (p<0.001). Retinal thickness at day-15 was 7.74 μm less in difluprednate-treated eyes (p=0.011).

loteprednol 0.5% suspension (Lotemax) versus prednisolone acetate

In 2 studies of acute anterior uveitis, loteprednol 0.5% suspension was compared to prednisolone acetate 1% for reduction in ocular signs and symptoms. Both studies were parallel, randomized, double-blind, active controlled comparisons. In the first study, treatment was administered 8 times daily and lasted for 42 days in 70 patients. The second study was 28 days in duration with initial treatment given 16 times daily in 175 patients. At the end of the first trial, 74% of loteprednol patients and 88% of prednisolone patients achieved resolution. The difference was not significant. In the second study, the 2 groups were not different with resolution rates of 72% for loteprednol and 87% for prednisolone groups. Elevated IOP was observed more frequently in the prednisolone group. This
A difference in resolution rates between loteprednol and prednisolone acetate appears in the prescribing information for loteprednol. The use of a more potent corticosteroid than loteprednol, such as prednisolone acetate 1%, is suggested for the treatment of anterior uveitis.

**Loteprednol 1% Suspension (Inveltys) versus Placebo**

In 2 multicenter, double-blind, placebo-controlled trials patients with an anterior cell grade ≥ 2 (a cell count of ≥ 6 using a slit-lamp biomicroscope) after cataract surgery were randomized to loteprednol or vehicle following surgery. Patients self-administered 1 to 2 drops of loteprednol (n=386 total) or vehicle (n=385 total) twice a day for 14 days, beginning the day after surgery. Complete resolution of inflammation was defined as a cell count of 0 maintained through day 15 without rescue medication. Complete resolution of pain was defined as pain grade of 0 maintained through day 15 without rescue medication. Across both studies, at days 8 and 15, significantly more patients treated with loteprednol versus placebo experienced complete resolution of inflammation (day 8: 24% versus 13%, respectively; day 15: 50% versus 27%, respectively). On days 4, 8, and 15, significantly more patients in the loteprednol group were pain-free compared to the placebo group (day 4: 43% versus 25%, respectively; day 8: 56% versus 36%, respectively; day 15: 69% versus 48%, respectively).

**Loteprednol 0.38% Gel (Lotemax SM) versus Placebo**

A multicenter, randomized, double-masked, vehicle-controlled study assessed the safety and efficacy of a 0.38% submicron (SM) formulation of loteprednol etabonate gel for the treatment of postoperative pain and inflammation in patients ≥ 18 years old who had undergone routine, uncomplicated cataract surgery (intent to treat, n=514). Patients were randomized 2:2:1:1 to receive loteprednol etabonate 0.38% gel 2 times daily (n=171), loteprednol etabonate 0.38% gel 3 times daily (n=172), or vehicle 2 or 3 times daily (n=172 total). The co-primary outcomes were the proportion of patients with anterior chamber cell resolution (cell score = 0) and absence of pain on postoperative day 8. On day 8, a greater percentage of loteprednol etabonate 0.38% gel-treated patients had a complete resolution of anterior chamber compared to those treated with vehicle (2 times daily, 26.9%; 3 times daily, 28.7%; vehicle, 9.3%; p<0.0001 for both versus vehicle). Likewise, a greater percentage of loteprednol etabonate 0.38% gel-treated patients had absence of pain on day 8 compared to those treated with vehicle (2 times daily, 75.4%; 3 times daily, 80.1%; vehicle, 47.1%; p<0.0001 for both versus vehicle). Adverse effects were comparable between groups and no patients discontinued loteprednol etabonate 0.38% gel due to a treatment-related adverse event.

**Implants, Inserts, and Injections**

**Dexamethasone Intracanalicular Insert (Dextenza) versus Placebo**

A multicenter, randomized, double-blind, controlled trial assessed the safety and efficacy of dexamethasone insert in patients with planned clear corneal cataract surgery (n=438). Patients were randomized 1:1 to receive 0.4 mg dexamethasone (inserted into the canaliculus immediately after surgery on day 1) or placebo. The co-primary outcomes were absence of anterior chamber cells on day 14 and absence of pain on day 8. On day 14, a greater percentage of dexamethasone insert-treated patients had absence of anterior chamber cells compared to those treated with placebo (52.3% versus 31.1%, respectively; p<0.0001). Likewise, on day 8, a greater percentage of dexamethasone insert-treated patients had absence of pain compared to those treated with placebo (79.6% versus 61.3%, respectively).
respectively; p<0.0001). Adverse effects were considered similar between groups. Decreased inflammation and pain were noted as early as days 4 and 2, respectively, in the treatment group.

dexamethasone intraocular suspension (Dexycu) versus placebo

A double-masked, placebo-controlled trial randomized 394 patients to dexamethasone suspension 517 mcg, dexamethasone 342 mcg, or vehicle administered by the physician at the end of unilateral cataract surgery. The proportion of patients with anterior chamber cell clearing (e.g., cell score = 0), on post-operative day 8, the primary efficacy endpoint, was 60%, 57%, and 20% in the respective groups. Anterior chamber cell clearing was measured up to 30 days after surgery and was reported in 66%, 72%, and 35% for dexamethasone 517 mcg and 342 mcg and placebo, respectively. The proportion of patients who required rescue therapy with an ocular corticosteroid or NSAIDs in the study eye by post-operative day 30 were 20% for patients treated with dexamethasone 517 mcg, 16% with dexamethasone 342 mcg, and 54% with placebo.

dexamethasone intravitreal implant (Ozurdex)

A study included 30 eyes of 30 patients to evaluate the efficacy and safety of dexamethasone intravitreal implant in patients with diabetic macular edema that was resistant to prior intravitreal bevacizumab therapy. At 1 and 3 months, the mean best corrected visual acuity (BCVA, logMAR) increased from 0.56 ± 0.38 to 0.41 (p<0.001), and 0.44 (p=0.008), respectively. At 1, 3, and 6 months, the mean central foveal thickness (CFT) decreased significantly from a baseline of 517 µm to 290 µm (p<0.001) at month 1, but significantly increased to 314 µm (p<0.003) and 411 µm (p=0.01) at months 3 and 6, respectively. Mean cub volume (MCV) significantly increased and BCVA significantly decreased from months 3 to 6. IOP measures were significantly higher at week 1 and months 1 and 3. Macular edema recurrence occurred in 25 eyes at 6 months. Researchers concluded that although dexamethasone intravitreal implant was safe and effective in treating patients resistant to bevacizumab, its efficacy decreased after 3 months.

Topical NSAIDs

diclofenac versus flurbiprofen

In a double-blind trial, 43 patients undergoing cataract extraction were randomized to diclofenac sodium 0.1% or flurbiprofen 0.03%. The assigned medication was instilled every 6 hours for 3 doses prior to surgery, then 4 drops over 90 minutes just prior to surgery. After surgery, patients administered the assigned medication 4 times daily for 3 to 6 weeks. Patients were examined 1, 3, and 6 weeks post-operatively. There were no statistically significant differences between the treatment groups for conjunctival hyperemia, corneal surface changes, IOP, or anterior chamber inflammation.

diclofenac versus ketorolac (Acular)

In a double-masked, randomized trial during the post-operative period of cataract extraction and implantation of an intraocular lens, a total of 120 patients were treated with either diclofenac 0.1% solution or ketorolac tromethamine 0.5% solution 4 times daily for 30 days. Treatment began the first post-operative day after surgery. Objective measurements of inflammation and toxicity were made at 3 post-operative visits. The anti-inflammatory effects were similar at all 3 post-operative visits. Both treatments were equally tolerated.
In a long-term follow-up to the above study, the primary endpoint was to evaluate the incidence of post-operative posterior opacification. Patients were followed for 3 years and received yttrium-aluminum-garnet (YAG) laser capsulotomies and were evaluated for any existing post-operative posterior opacification. The incidence of post-operative posterior opacification and YAG capsulotomies were similar (12% in each treatment group). Adverse effects from therapy were also similar in both groups.

In a double-blind, randomized study, diclofenac 0.1% solution and ketorolac 0.5% solution were compared in 30 patients for efficacy in relieving corneal pain after refractive surgery. Patients underwent radial keratotomy and were monitored for post-operative pain and instillation comfort. Both diclofenac and ketorolac were similarly effective in reducing ocular pain and had similar comfort on instillation (p=0.29).

**ketorolac 0.5% (Acular) versus ketorolac 0.4% (Acular LS)**

The 2 formulations of ketorolac tromethamine 0.4% and 0.5% ophthalmic solutions were compared for effectiveness and patient tolerance in 40 patients undergoing phacoemulsification and lens implantation. In a double-masked study, patients were randomized to receive 1 of the 2 strengths of ketorolac starting 15 minutes prior to surgery. After surgery, patients administered 1 drop 4 times daily for 1 week, then twice daily for 3 weeks. Patients were examined on day-1, -7, and -30. On day-1, more patients reported foreign body sensation or stinging and burning in the ketorolac 0.5% group (70%) than the ketorolac 0.4% group (40%; p<0.05). There were no significant differences between the 2 groups for best-corrected visual acuity, IOP, slit-lamp assessment of cells, or cell/flare measured using the laser cell/flare meter.

**ketorolac (Acular) versus loteprednol suspension (Lotemax)**

In a randomized, double-blind trial looking at controlling inflammation after cataract surgery, 60 patients were randomized to receive ketorolac tromethamine 0.5% or loteprednol etabonate 0.5% suspension 4 times a day starting 24 hours after surgery. There was no statistically significant difference in any measurement of post-operative inflammation between the 2 groups measured by external slit-lamp examination on post-operative days 1, 4, 7, and 30.

**ketorolac (Acular LS) versus nepafenac (Nevanac)**

A randomized study compared the efficacy of ketorolac tromethamine 0.4% and nepafenac 0.1% eye drops for prophylaxis of cystoid macular edema (CME) after small-incision cataract extraction. The incidence and severity of CME were evaluated by retinal foveal thickness on optical coherence tomography (OCT) after 1, 4 and 12 weeks in patients who were randomized to ketorolac tromethamine 0.4%, nepafenac 0.1%, or placebo. One hundred and twenty-six eyes of 126 patients were included were evaluated. The between-group differences in visual outcomes, central corneal thickness and endothelial cell density, or measurements performed by spectral-domain OCT were not statistically significant.

**ketorolac (Acular) versus prednisolone acetate**

In a double-blind trial, 59 patients requiring cataract extraction were randomized to receive either ketorolac tromethamine 0.5% solution or prednisolone acetate 1%. Treatment was administered according to the following schedule: 1 to 2 drops 4 times daily for 1 week; 3 times daily for the second week; 2 times daily for the third week; and once daily for the fourth week. At day 28, both treatments
produced comparable reductions in intraocular inflammation and pain after cataract surgery and were well tolerated by patients. No adverse events were reported.

**nepafenac 0.3% (Ilevro) versus nepafenac 0.1% (Nevanac) versus placebo**

In 2 double-masked, randomized clinical trials, nepafenac ophthalmic suspensions 0.3% and 0.1% were compared to vehicle dosed daily starting 1 day prior to cataract surgery, continued on the day of surgery, and for the first 2 weeks post-operatively.³⁰⁸ Nepafenac suspension showed better clinical efficacy compared to its vehicle. In the first study, inflammation resolved at post-operative day 14 in 65% of nepafenac ophthalmic suspension 0.3% patients (n=851), in 32% of vehicle patients (n=211), and in 67% of nepafenac ophthalmic suspension 0.1% patients (n=845). Ocular pain at day 14 resolved in 86% of nepafenac 0.3% patients, 46% of placebo patients, and 87% of nepafenac 0.1% patients. In the second study, nepafenac 0.3% (n=540) resolved inflammation (post-operative day 14) versus vehicle (n=268) in 61% and 24% of patients, respectively. Ocular pain resolved in 84% and 38% of nepafenac 0.3% and vehicle groups, respectively.

**META-ANALYSES**

A meta-analysis comparing dexamethasone 0.7 mg implant (Ozurdex) with anti-vascular endothelial growth factor (anti-VEGF) therapy (bevacizumab and ranibizumab) in patients with DME included 4 randomized clinical trials (published between 2014 and 2016) with a total of 521 eyes.³⁰⁹ Treatment with dexamethasone implant achieved similar improvement in visual acuity as anti-VEGF therapy based at 6 months as reported by mean difference in best-corrected visual acuity (BCVA) of -0.43 (95% CI, -1.32 to 0.47; p=0.35); however, in 2 studies (451 eyes), statistically significant differences favoring anti-VEGF therapy were found at 12 months (mean difference in BCVA was -3.26 [95% CI, -4.66 to -1.86; p<0.00001]). Heterogeneity of the studies measuring BCVA was low. Three studies (157 eyes) favored dexamethasone based on mean difference in central subfield thickness (CST) at month 6 but not at month 12. Heterogeneity regarding CST, however, was high. While not statistically significant, the findings favored dexamethasone regarding serious adverse events, including increased IOP, cataract, and vitreous hemorrhage.

A meta-analysis compared the efficacy and safety of dexamethasone 0.7 mg implant (Ozurdex) to anti-VEGF therapy (ranibizumab and bevacizumab) in patients with macular edema (ME) secondary to branch retinal vein occlusion (BRVO).³¹⁰ The meta-analysis included 6 studies (published between 2015 and 2018) and a total of 452 eyes with outcomes of best-corrected visual acuity (BCVA), central macular thickness (CMT), and adverse events. Treatment with dexamethasone implant achieved a significant mean difference in BCVA compared to anti-VEGF therapy at 1 month (mean difference, -0.11 [95% CI, -0.16 to -0.06; p<0.00001]) and at 3 months (mean difference -0.06 [95% CI, -0.11 to -0.0; p=0.03]). In addition, mean change in BCVA from baseline at 1 month was significantly better with dexamethasone compared to anti-VEGF (mean difference, -0.35 [95% CI, -0.49 to -0.2; p<0.00001]) at 1 month. No significant differences in BCVA between dexamethasone implant and anti-VEGF therapy were found at 6 months or in the mean BCVA change from baseline at 3 or 6 months. Heterogeneity was high between the 2 studies assessing BCVA from baseline at 1 month; however, no heterogeneity was detected in the other studies measuring BCVA. Treatment with dexamethasone implant reduced CMT at 1 month significantly more than anti-VEGF treatment, but this efficacy was not maintained at 3 and 6 months. Heterogeneity was significant between studies assessing CMT at 3 and 6 months. The dexamethasone group had a significantly higher risk of elevated IOP compared to anti-VEGF. The
incidence of cataract was higher in the dexamethasone group than in the anti-VEGF group, but this difference was not significant.

SUMMARY

Ophthalmic corticosteroids have long been used as first-line therapy for the treatment of ophthalmic inflammatory conditions prior to the increased use of ophthalmic NSAIDs. The ophthalmic NSAIDs offer equivalent anti-inflammatory efficacy for post-operative inflammation. Ophthalmic corticosteroids have the potential for long-term adverse events, such as increased intraocular pressure (IOP), cataract formation and increased risk of ocular infection, but studies comparing ophthalmic corticosteroids to ophthalmic NSAIDs have not shown clinical differences in adverse event profiles when treatment duration is 30 days or less. There are no data to suggest a significant advantage for any one product in either subclass in terms of clinical effectiveness or adverse effect profile, nor are there data that show a difference between agents in different subclasses.

Products with invasive (e.g., intravitreal) administration (Iluvien, Retisert, Triesence, Ozurdex, Yutiq) are available and injected or implanted by a licensed healthcare professional. These agents (Ozurdex, Retisert, Triesence, Yutiq) are approved to treat uveitis, typically when topical therapy fails. In addition, dexamethasone (Ozurdex) and fluocinolone (Iluvien) implants are indicated to treat diabetic macular edema. Dexamethasone implant is also indicated to treat macular edema following branch/central retinal vein occlusion.

Dexamethasone intraocular suspension (Dexycu) is also available for administration as a single injection by a healthcare professional at the end of ocular surgery to treat post-operative inflammation. It is the first long-acting intraocular corticosteroid that replaces the need for patient- or caregiver-administered corticosteroid drops after cataract surgery. Similarly, dexamethasone intracanalicular insert (Dextenza) is administered by a healthcare professional and is approved for the treatment of pain and inflammation following ophthalmic surgery.

REFERENCES

1 Maxidex [package insert]. Fort Worth, TX; Alcon; May 2018.
3 Durezol [package insert]. Fort Worth TX; Alcon; April 2017.
7 Flarex [package insert]. Fort Worth, TX; Alcon; March, 2017.
8 Inveltys [package insert]. Waltham, MA; Kala; August 2018.
13 Omnipred [package insert]. Fort Worth, TX; Alcon; October 2007.
14 Pred Forte [package insert]. Irvine, CA; Allergan; June 2018.
15 Pred Mild [package insert]. Irvine, CA; Allergan; June 2018.
17 Dexycu [package insert]. Watertown, MA; EyePoint; December 2018.
18 Ozurdex [package insert]. Irvine, CA; Allergan; May 2018.
20 Yutiq [package insert]. Watertown, MA; EyePoint; October 2018.
23 Triensce [package insert]. Fort Worth, TX; Alcon; November 2007.
24 Prolensa [package insert]. Tampa, FL; Bausch & Lomb; June 2016.
27 Voltaren [package insert]. Duluth, GA; Novartis; September 2012.
29 Aculsr LS [package insert]. Irvine, CA; Allergan; June 2016.
30 Acuvail [package insert]. Irvine, CA; Allergan; February 2019.
31 Aculsr [package insert]. Irvine, CA; Allergan; June 2012.
32 Ilevel [package insert]. Fort Worth, TX; Alcon; January 2019.
33 Nevanac [package insert]. Fort Worth, TX; Alcon; January 2019.
45 Maxidex [package insert]. Fort Worth, TX; Alcon; May 2018.
47 Durezol [package insert]. Fort Worth, TX; Alcon; April 2017.
52 Fluorex [package insert]. Fort Worth, TX; Alcon; March, 2017.
53 Inveltys [package insert]. Waltham, MA; Kala; August 2018.
55 Econopred Plus [package insert]. Fort Worth, TX; Alcon; August 2002.
56 Omnipred [package insert]. Fort Worth, TX; Alcon; October 2007.
57 Pred Forte [package insert]. Irvine, CA; Allergan; June 2016.
58 Pred Mild [package insert]. Irvine, CA; Allergan; June 2018.
60 Triensce [package insert]. Fort Worth, TX; Alcon; November 2007.
63 Aculsr LS [package insert]. Irvine, CA; Allergan; June 2016.
64 Aculsr [package insert]. Irvine, CA; Allergan; June 2012.
65 Nevanac [package insert]. Fort Worth, TX; Alcon; January 2019.
66 O dourex [package insert]. Irvine, CA; Allergan; September 2012.
67 Acuvail [package insert]. Irvine, CA; Allergan; February 2019.
68 Ilevel [package insert]. Fort Worth, TX; Alcon; January 2019.
69 Nevanac [package insert]. Fort Worth, TX; Alcon; January 2019.
70 Prolensa [package insert]. Tampa, FL; Bausch & Lomb; June 2016.
71 Bromsite [package insert]. Cranbury, NJ; Sun; April 2016.
72 Dexcu [package insert]. Watertown, MA; EyePoint; December 2018.
73 Yutio [package insert]. Watertown, MA; EyePoint; October 2018.
75 Maxidex [package insert]. Fort Worth, TX; Alcon; May 2018.
77 Durezol [package insert]. Fort Worth TX; Alcon; April 2017.
82 Invefts [package insert]. Waltham, MA; Kala; August 2018.
83 Florac [package insert]. Fort Worth, TX; Alcon; March, 2017.
85 Omnipred [package insert]. Fort Worth, TX; Alcon; October 2007.
86 Pred Forte [package insert]. Irvine, CA; Allergan; June 2018.
87 Pred Mild [package insert]. Irvine, CA; Allergan; June 2018.
89 Triessen [package insert]. Fort Worth, TX; Alcon; November 2007.
93 Acular [package insert]. Irvine, CA; Allergan; June 2012.
94 Nevanac [package insert]. Fort Worth, TX; Alcon; January 2019.
95 Ozurdex [package insert]. Irvine, CA; Allergan; May 2018.
96 Acuvail [package insert]. Irvine, CA; Allergan; February 2019.
97 Ilevro [package insert]. Fort Worth, TX; Alcon; January 2019.
98 Nevanac [package insert]. Fort Worth, TX; Alcon; January 2019.
100 Bromsite [package insert]. Cranbury, NJ; Sun; April 2012.
101 Dexycu [package insert]. Watertown, MA; EyePoint; December 2018.
102 Yutiq [package insert]. Watertown, MA; EyePoint; October 2018.
109 Acular [package insert]. Irvine, CA; Allergan; June 2012.
111 Acuvail [package insert]. Irvine, CA; Allergan; February 2019.
112 Nevanac [package insert]. Fort Worth, TX; Alcon; January 2019.
115 Bromday [package insert]. Tampa, FL; Bausch & Lomb; October 2012.
120 Maxidex [package insert]. Fort Worth, TX; Alcon; May 2018.
122 Durezol [package insert]. Fort Worth TX; Alcon; April 2017.
127 Invefts [package insert]. Waltham, MA; Kala; August 2018.
128 Flarex [package insert]. Fort Worth, TX; Alcon; March, 2017.
130 Econopred Plus [package insert]. Fort Worth, TX; Alcon; August 2002.
131 Omnipred [package insert]. Fort Worth, TX; Alcon; October 2007.
132 Pred Forte [package insert]. Irvine, CA; Allergan; June 2018.
133 Pred Mild [package insert]. Irvine, CA; Allergan; June 2018.

135 Triesence [package insert]. Fort Worth, TX; Alcon; November 2007.


139 Acular [package insert]. Irvine, CA; Allergan; June 2012.

140 Nevanac [package insert]. Fort Worth, TX; Alcon; January 2019.

141 Ozurdex [package insert] Irvine, CA; Allergan; September 2012.

142 Acuvail [package insert]. Irvine, CA; Allergan; February 2019.

143 Ilevro [package insert]. Fort Worth, TX; Alcon; January 2019.


145 Nevanac [package insert]. Fort Worth, TX; Alcon; January 2019.

146 Proloens [package insert]. Tampa, FL; Bausch & Lomb; June 2016.

147 Bromsite [package insert]. Cranbury, NJ; Sun; April 2016.

148 Dexycu [package insert]. Watertown, MA; EyePoint; December 2018.


155 Maxidex [package insert]. Fort Worth, TX; Alcon; May 2018.


157 Durezol [package insert]. Fort Worth TX; Alcon; April 2017.


162 Inveltys [package insert]. Waltham, MA; Kala; August 2018.

163 Iirex [package insert]. Fort Worth, TX; Alcon; March, 2017.


165 Econopred Plus [package insert]. Fort Worth, TX; Alcon; August 2002.

166 Omnipred [package insert]. Fort Worth, TX; Alcon; October 2007.

167 Pred Mild [package insert]. Irvine, CA; Allergan; June 2018.


169 Pred Forte [package insert]. Irvine, CA; Allergan; June 2018.

170 Triesence [package insert]. Fort Worth, TX; Alcon; November 2007.


174 Acular [package insert]. Irvine, CA; Allergan; June 2012.

175 Nevanac [package insert]. Fort Worth, TX; Alcon; January 2019.

176 Acuvail [package insert]. Irvine, CA; Allergan; February 2019.

177 Ilevro [package insert]. Fort Worth, TX; Alcon; January 2019.


179 Nevanac [package insert]. Fort Worth, TX; Alcon; January 2019.

180 Proloens [package insert]. Tampa, FL; Bausch & Lomb; June 2016.


182 Dexycu [package insert]. Watertown, MA; EyePoint; December 2018.

183 Yutiq [package insert]. Watertown, MA; EyePoint; October 2018.


186 Maxidex [package insert]. Fort Worth, TX; Alcon; May 2018.


188 Durezol [package insert]. Fort Worth TX; Alcon; April 2017.


192 Inveoleys [package insert]. Waltham, MA; Kala; August 2018.
193 Flarex [package insert]. Fort Worth, TX; Alcon; March, 2017.
198 Omnirin [package insert]. Fort Worth, TX; Alcon; October 2007.
199 Pred Forte [package insert]. Irvine, CA; Allergan; June 2018.
200 Pred Mild [package insert]. Irvine, CA; Allergan; June 2018.
202 Ozurdex [package insert]. Irvine, CA; Allergan; May 2018.
204 Retisert [package insert]. Rochester, NY; Bausch & Lomb; December 2017.
205 Triesence [package insert]. Fort Worth, TX; Alcon; November 2007.
206 Prolensa [package insert]. Tampa, FL; Bausch & Lomb; June 2016.
207 Bromside [package insert]. Cranbury, NJ; Sun; April 2016.
211 Acular [package insert]. Irvine, CA; Allergan; June 2012.
213 Acuvail [package insert]. Irvine, CA; Allergan; February 2019.
214 Ilevro [package insert]. Fort Worth, TX; Alcon; January 2019.
216 Dexycu [package insert]. Watertown, MA; EyePoint; December 2018.
217 Yutiq [package insert]. Watertown, MA; EyePoint; October 2018.
224 Durezol [package insert]. Fort Worth TX; Alcon; April 2017.
227 Durezol [package insert]. Fort Worth TX; Alcon; April 2017.
228 Retisert [package insert]. Rochester, NY; Bausch & Lomb; December 2017.
232 Flarex [package insert]. Fort Worth, TX; Alcon; March, 2017.
233 Inveoleys [package insert]. Waltham, MA; Kala; August 2018.
235 Ecomopod Plus [package insert]. Fort Worth, TX; Alcon; August 2002.
236 Omnirin [package insert]. Fort Worth, TX; Alcon; October 2007.
237 Pred Forte [package insert]. Irvine, CA; Allergan; June 2018.
238 Pred Mild [package insert]. Irvine, CA; Allergan; June 2018.
240 Triesence [package insert]. Fort Worth, TX; Alcon; November 2007.
244 Acular [package insert]. Irvine, CA; Allergan; June 2012.
245 Nevanac [package insert]. Fort Worth, TX; Alcon; January 2019.
246 Ozurdex [package insert]. Irvine, CA; Allergan; September 2012.
248 Ilevro [package insert]. Fort Worth, TX; Alcon; January 2019.
249 Prolensa [package insert]. Tampa, FL; Bausch & Lomb; June 2016.
251 Nevanac [package insert]. Fort Worth, TX; Alcon; January 2019.
253 Dexycu [package insert]. Watertown, MA; EyePoint; December 2018.
254 Yutiq [package insert]. Watertown, MA; EyePoint; October 2018.
259 Maxidex [package insert]. Fort Worth, TX; Alcon; May 2018.
261 Durezol [package insert]. Fort Worth TX; Alcon; April 2017.
265 Flarex [package insert]. Fort Worth, TX; Alcon; March, 2017.
266 Invefts [package insert]. Waltham, MA; Kala; August 2018.
271 Omnipred [package insert]. Fort Worth, TX; Alcon; October 2007.
272 Pred Forte [package insert]. Irvine, CA; Allergan; June 2018.
275 Ozurdex [package insert]. Irvine, CA; Allergan; May 2018.
278 Trience [package insert]. Fort Worth, TX; Alcon; November 2007.
279 Prolensa [package insert]. Tampa, FL; Bausch & Lomb; June 2016.
283 Ocufen [package insert]. Irvine, CA; Allergan; July 2012.
286 Acular [package insert]. Irvine, CA; Allergan; June 2012.
287 Illevro [package insert]. Fort Worth, TX; Alcon; January 2019.
288 Nevanac [package insert]. Fort Worth, TX; Alcon; January 2019.
289 Dexycu [package insert]. Watertown, MA; EyePoint; December 2018.
290 Yutiq [package insert]. Watertown, MA; EyePoint; October 2018.
295 Invefts [package insert]. Waltham, MA; Kala; August 2018.
298 Dexycu [package insert]. Watertown, MA; EyePoint; December 2018.
301 Flach AJ, Dolan BJ, Donahue ME, et al. Comparative effects of ketorolac 0.5% or diclofenac 0.1% ophthalmic solutions on inflammation after cataract surgery. Ophthalmology. 1998; 105(9):1775-1779.
302 Flach AJ, Dolan BJ. Incidence of postoperative posterior opacification following treatment with diclofenac 0.1 percent and ketorolac 0.5 percent ophthalmic solutions: 3-year randomized, double-masked, prospective clinical investigation. Trans Am Ophthalmol Soc. 2000; 98:101-105.
308 llovo [package insert]. Fort Worth, TX; Alcon; January 2019.